Taken together, these data suggest that nilotinib particularly targets CD34+CD38− stem cells and MDR leukemia cells, and effectively enhances the efficacy of chemotherapeutic drugs by blocking the efflux function of ABC transporters. Here, CD38 is linked to leukemia.